Table 3.
Univariate and multivariate analyses of prognostic significance of TG/HDL-C levels.
| Training cohort | Test cohort | |||||
|---|---|---|---|---|---|---|
| Variable | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||
| P | HR (95%CI) | P | P | HR (95%CI) | P | |
| Age | 0.015 | 1.13 (1.06-1.57) | 0.001 | 0.021 | 1.21 (1.02-1.82) | 0.045 |
| Gender (Male) | 0.301 | 0.358 | ||||
| Smoking | 0.540 | 0.165 | ||||
| Drinking | 0.308 | 0.607 | ||||
| Helicobator pylori | 0.814 | 0.274 | ||||
| Differentiation | <0.001 | 0.001 | ||||
| Well | Reference | Reference | ||||
| Moderate/Poor | 1.24 (0.65-1.62) | 0.268 | 1.54 (0.86-2.65) | 0.259 | ||
| pT stage | <0.001 | <0.001 | ||||
| T1-T2 | Reference | Reference | ||||
| T3-T4 | 1.85 (1.12-3.88) | 0.011 | 1.94 (1.10-3.01) | <0.001 | ||
| pN stage | <0.001 | <0.001 | ||||
| N0 | Reference | Reference | ||||
| N1-N3 | 1.92 (1.14-3.18) | <0.001 | 1.63 (1.10-3.05) | 0.002 | ||
| Metastasis | <0.001 | <0.001 | ||||
| Absent | Reference | Reference | ||||
| Present | 1.94 (1.26-2.78) | <0.001 | 2.11 (1.41-3.05) | <0.001 | ||
| Chemotherapy | 0.415 | 0.208 | ||||
| Treatments | <0.001 | <0.001 | ||||
| Curative | Reference | Reference | ||||
| Palliative | 1.46 (0.94-1.89) | 0.127 | 1.49 (0.92-2.59) | 0.098 | ||
| TG (mmol/L) | 0.006 | 0.85 (0.51-0.94) | 0.033 | <0.001 | 0.78 (0.52-0.90) | 0.040 |
| TC (mmol/L) | 0.138 | 0.756 | ||||
| HDL-C (mmol/L) | 0.002 | 0.92 (0.84-1.51) | 0.614 | 0.054 | ||
| TG/HDL-C | <0.001 | 0.65 (0.32-0.92) | 0.001 | <0.001 | 0.64 (0.45-0.91) | 0.004 |
TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG/HDL-C, TG to HDL-C ratio; HR, hazard ratio; CI, confidence interval.